Vol 75, No 1 (2024)
Review article
Published online: 2024-03-29

open access

Page views 162
Article views/downloads 111
Get Citation

Connect on Social Media

Connect on Social Media

Praziquantel as the preferred treatment for schistosomiasis

Yusuf Haz Condeng1, Sudirman Katu1, Andi Makbul Aman1, Haerani Rasyid1, Syakib Bakri1, Harun Iskandar1
DOI: 10.5603/imh.99453
Pubmed: 38647059
IMH 2024;75(1):49-54.

Abstract

Schistosomiasis, caused by Schistosoma trematode worms, represents a significant global health challenge.
This review offers a thorough examination of the disease’s epidemiology, transmission dynamics, diagnostic
modalities, and treatment options. Diagnostic techniques encompass direct parasitological methods,
immunological assays, DNA/RNA detection, and biomarker utilization, each with distinct advantages and limitations.
There is an urgent need for improved diagnostic tools with enhanced sensitivity and specificity.
Praziquantel remains the cornerstone of treatment, exhibiting efficacy against all Schistosoma species,
while the potential of artemisin derivatives in combination therapy is also explored. In this review, we focus
on the importance of praziquantel administration as the central aspect of schistosomiasis treatment,
highlighting ongoing efforts to optimize its utilization for improved patient outcomes.

Article available in PDF format

View PDF Download PDF file

References

  1. Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis. Lancet. 2014; 383(9936): 2253–2264.
  2. McManus D, Dunne D, Sacko M, et al. Schistosomiasis. Nat Rev Dis Primers. 2018; 4(1).
  3. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006; 368(9541): 1106–1118.
  4. LoVerde PT. Schistosomiasis. Adv Exp Med Biol. 2019; 1154: 45–70.
  5. Ajibola O, Gulumbe BH, Eze AA, et al. Tools for detection of schistosomiasis in resource limited settings. Med Sci (Basel). 2018; 6(2).
  6. Utzinger J, Becker SL, van Lieshout L, et al. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015; 21(6): 529–542.
  7. Weerakoon KG, Gobert GN, Cai P, et al. Advances in the diagnosis of human schistosomiasis. Clin Microbiol Rev. 2015; 28(4): 939–967.
  8. Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: clinical perspective: review. J Adv Res. 2013; 4(5): 433–444.
  9. Zhang YY, Luo JP, Liu YM, et al. Evaluation of Kato-Katz examination method in three areas with low-level endemicity of schistosomiasis japonica in China: A Bayesian modeling approach. Acta Trop. 2009; 112(1): 16–22.
  10. Yu JM, de Vlas SJ, Jiang QW, et al. Comparison of the Kato-Katz technique, hatching test and indirect hemagglutination assay (IHA) for the diagnosis of Schistosoma japonicum infection in China. Parasitol Int. 2007; 56(1): 45–49.
  11. Zhu YC. Immunodiagnosis and its role in schistosomiasis control in China: a review. Acta Trop. 2005; 96(2-3): 130–136.
  12. Smith H, Doenhoff M, Aitken C, et al. Comparison of Schistosoma mansoni soluble cercarial antigens and soluble egg antigens for serodiagnosing schistosome infections. PLoS Negl Trop Dis. 2012; 6(9): e1815.
  13. Zhu Y, He W, Liang Y, et al. Development of a rapid, simple dipstick dye immunoassay for schistosomiasis diagnosis. J Immunol Methods. 2002; 266(1-2): 1–5.
  14. Carvalho do Espírito-Santo MC, Pinto PL, Gargioni C, et al. Detection of Schistosoma mansoni antibodies in a low-endemicity area using indirect immunofluorescence and circumoval precipitin test. Am J Trop Med Hyg. 2014; 90(6): 1146–1152.
  15. Gomes LI, Enk MJ, Rabello A. Diagnosing schistosomiasis: where are we? Rev Soc Bras Med Trop. 2014; 47(1): 3–11.
  16. Cai YC, Xu JF, Steinmann P, et al. Field comparison of circulating antibody assays versus circulating antigen assays for the detection of schistosomiasis japonica in endemic areas of China. Parasit Vectors. 2014; 7: 138.
  17. Sarhan RM, Aminou HA, Saad GA, et al. Comparative analysis of the diagnostic performance of adult, cercarial and egg antigens assessed by ELISA, in the diagnosis of chronic human Schistosoma mansoni infection. Parasitol Res. 2014; 113(9): 3467–3476.
  18. van Lieshout L, Polderman AM, Deelder AM. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections. Acta Trop. 2000; 77(1): 69–80.
  19. Grenfell RF, Coelho PM, Taboada D, et al. Newly established monoclonal antibody diagnostic assays for Schistosoma mansoni direct detection in areas of low endemicity. PLoS One. 2014; 9(1): e87777.
  20. Lier T, Simonsen G, Wang T, et al. Real-Time polymerase chain reaction for detection of low-intensity schistosoma japonicum infections in China. Am J Trop Med Hyg. 2009; 81(3): 428–432.
  21. Wichmann D, Poppert S, Von Thien H, et al. Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis. BMC Infect Dis. 2013; 13: 55.
  22. Chen Xi, Liang H, Zhang J, et al. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012; 22(3): 125–132.
  23. Xu J, Rong R, Zhang HQ, et al. Sensitive and rapid detection of Schistosoma japonicum DNA by loop-mediated isothermal amplification (LAMP). Int J Parasitol. 2010; 40(3): 327–331.
  24. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000; 28(12): E63.
  25. Chuah C, Jones MK, Burke ML, et al. Cellular and chemokine-mediated regulation in schistosome-induced hepatic pathology. Trends Parasitol. 2014; 30(3): 141–150.
  26. Li JV, Saric J, Wang Y, et al. Chemometric analysis of biofluids from mice experimentally infected with Schistosoma mansoni. Parasit Vectors. 2011; 4: 179.
  27. Liu F, Lu J, Hu W, et al. New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog. 2006; 2(4): e29.
  28. Zhong Zr, Zhou Hb, Li Xy, et al. Serological proteome-oriented screening and application of antigens for the diagnosis of Schistosomiasis japonica. Acta Trop. 2010; 116(1): 1–8.
  29. Ross AGP, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002; 346(16): 1212–1220.
  30. Shiha G, Sarin SK, Ibrahim AE, et al. Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009; 3(2): 323–333.
  31. Ross AG, McManus DP, Farrar J, et al. Neuroschistosomiasis. J Neurol. 2012; 259(1): 22–32.
  32. Ferrari TC, Moreira PR. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol. 2011; 10(9): 853–864.
  33. ZHOU YB, ZHAO GM, PENG WX, et al. Field comparison of immunodiagnostic and parasitological techniques for the detection of schistosomiasis japonica in the People’s Republic of China. Am J Trop Med Hyg. 2007; 76(6): 1138–1143.
  34. Stothard JR. Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model. Trans R Soc Trop Med Hyg. 2009; 103(4): 325–332.
  35. Rollinson D, Knopp S, Levitz S, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop. 2013; 128(2): 423–440.
  36. El Ridi RAF, Tallima HAM. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res. 2013; 4(5): 467–478.
  37. Inobaya MT, Olveda RM, Chau TNp, et al. Prevention and control of schistosomiasis: a current perspective. Res Rep Trop Med. 2014; 2014(5): 65–75.
  38. Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, et al. Population pharmacokinetics and pharmacodynamics of praziquantel in ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. mBio. 2016; 7(4).
  39. Adam I, Elhardello OA, Elhadi MO, et al. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol. 2008; 102(1): 39–44.
  40. Mnkugwe RH, Minzi O, Kinung'hi S, et al. Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. PLoS Negl Trop Dis. 2020; 14(9): e0008619.
  41. Nogueira RA, Lira MG, Licá IC, et al. Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol. 2022; 252: 111531.
  42. You H, McManus DP, Hu W, et al. Transcriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII. PLoS Pathog. 2013; 9(3): e1003254.
  43. Liu R, Dong HF, Guo Yi, et al. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011; 4: 201.